← Eichor
Condition: Malignant Pleural Mesothelioma Advanced Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Malignant Pleural Mesothelioma Advanced

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Phase 2 · 2 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05188859A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic
Phase 2 · 97 location(s) · AstraZeneca · NCT06535607Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
NA · 1 location(s) · University of Chicago · NCT07126509CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 · 16 location(s) · IDEAYA Biosciences · NCT07277413A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
Phase N/A · 1 location(s) · Tianjin Medical University Second Hospital · NCT06031636A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695Evaluation of Skin Tests in Biotherapy Allergies
NA · 1 location(s) · University Hospital, Angers · NCT06971848A Study of MT027 in Patients with Pleural Malignant Tumors
Phase 1 · 1 location(s) · Suzhou Maximum Bio-tech Co., Ltd. · NCT06726564Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Phase 1 · 10 location(s) · InSilico Medicine Hong Kong Limited · NCT06566079HTL0039732 in Participants With Advanced Solid Tumours
Phase 1/Phase 2 · 5 location(s) · Cancer Research UK · NCT05944237APG-2449 in Patients With Advanced Solid Tumors
Phase 1 · 9 location(s) · Ascentage Pharma Group Inc. · NCT03917043SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Phase 1 · 5 location(s) · Verismo Therapeutics · NCT05568680SW-682 in Advanced Solid Tumors
Phase 1 · 8 location(s) · SpringWorks Therapeutics, Inc., a healthcare company of Merc · NCT06251310A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/Phase 2 · 81 location(s) · Novartis Pharmaceuticals · NCT04104776
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.